Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies
But Exchange Rate Headwinds
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.
You may also be interested in...
French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics.
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.